MYOMO, INC.
MYONYSEHealthcare · Orthopedic, Prosthetic & Surgical Appliances & Supplies · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $40.9M | $32.6M | $19.2M | $15.6M | $13.9M | $7.6M |
| Operating income | −$14.4M | −$6.2M | −$8.2M | −$10.7M | −$10.3M | −$10.5M |
| Net income | −$15.6M | −$6.2M | −$8.1M | −$10.7M | −$10.4M | −$11.6M |
| Total assets | $38.6M | $42.2M | $14.6M | $10.2M | $20.1M | $14.7M |
| Total liabilities | $27.2M | $17.5M | $5.6M | $3.8M | $4.7M | $3.1M |
| Equity | $11.4M | $24.7M | $9.0M | $6.4M | $15.4M | $11.6M |
| EPS (diluted) | $-0.37 | $-0.16 | $-0.28 | $-1.52 | $-1.89 | — |
| Shares out. | 34.4M | 28.5M | 20.9M | 6.9M | 5.6M | 2.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −35.2%
- Net margin
- −38.1%
- Return on equity
- −136.6%
- Return on assets
- −40.3%
- Return on capital (ROCE)
- −47.5%
- Liabilities / assets
- 70.5%
- Debt / equity
- 2.39×
- Book value / share
- $0.33
- Revenue growth (YoY)
- 25.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -8.82distress
- Accruals / assets
- −2.7%clean
- Beneish M-Score
- -2.71normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Horton Capital Partners, LlcActivist (13D)May 18, 2026
- Rosalind Advisors, Inc.Passive (13G)Feb 11, 2026
- Hirschman OrinPassive (13G)Nov 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Kirk Thomas FDirector | May 28, 2026 | Buy | 25,000 | $0.99 |
| Kovelman HarryOfficer — Chief Medical Officer | May 27, 2026 | Sell | 20,464 | $1.00 |
| Kirk Thomas FDirector | May 15, 2026 | Buy | 31,605 | $0.91 |
| Manko Joseph M. Jr.Director | May 14, 2026 | Buy | 170,830 | $0.86 |
| Mitchell MicahOfficer — Chief Commercial Officer | May 14, 2025 | Sell | 90,231 | $0.86 |
| Febbo William JDirector | Apr 14, 2026 | Grant | 45,000 | $0.00 |
| Gudonis Paul ROfficer — Chief Executive Officer | Jan 12, 2026 | Grant | 11,637 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.8M | 9.2 | -0.8% |
| Apr 30, 2026 | 3.8M | 13.1 | -1.3% |
| Apr 15, 2026 | 3.9M | 15.2 | +2.8% |
| Mar 31, 2026 | 3.8M | 12.6 | -22.6% |
| Mar 13, 2026 | 4.9M | 9.2 | +6.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Regulation FD disclosureMay 13, 2026
- Results of operationsMay 7, 2026
- Director / officer change · Regulation FD disclosureApr 16, 2026
- Results of operationsMar 9, 2026
- Director / officer changeDec 16, 2025
- Entered a material agreement · Results of operations · New financial obligation · Unregistered equity saleNov 10, 2025
- Results of operationsAug 11, 2025
- Regulation FD disclosureJun 18, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4Jun 1, 2026
- 4May 28, 2026
- 144May 28, 2026
- SDMay 28, 2026
- 144May 27, 2026
- 4May 18, 2026
- SCHEDULE 13D/AMay 18, 2026
- 4PRIMARY DOCUMENTMay 18, 2026
- 3PRIMARY DOCUMENTMay 18, 2026
- 4May 15, 2026
- 144May 14, 2026
- ARSMay 14, 2026
- DEFA14AMay 14, 2026
- DEF 14AMay 14, 2026
- 8-KMay 13, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.